89bio to Participate in the Cantor Global Healthcare Conference

9/21, 2:00 PM (Source: GlobeNewswire)

89bio-2.05%

17.66
Chart for: 89bio

SAN FRANCISCO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Cantor Global Healthcare Conference, a virtul event, on Tuesday, September 28, 2021 at 2:40 p.m. ET.

The webcast of the presentation will be accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com

 


Primary Logo

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.